Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery

WU Tao; WANG Xiumei; ZHU Liping; FU Lati; OU Jianghua; NI Duo

doi:10.3971/j.issn.1000-8578.2013.10.012

Cancer Research on Prevention and Treatment > 2013 > 40(10): 966-968. > DOI: 10.3971/j.issn.1000-8578.2013.10.012

WU Tao, WANG Xiumei, ZHU Liping, FU Lati, OU Jianghua, NI Duo. Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 966-968. DOI: 10.3971/j.issn.1000-8578.2013.10.012

Citation:

PDF (929 KB)

Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery

1.Department of Breast Surgery, Affiliated Tumour Hospital, Xinjiang Medical University,Urumqi 830011, China,2. Office of Hospital,3. Department of Evidence-based Medicine and Clinical Epidemiology

More Information

Received Date: November 04, 2012
Revised Date: November 29, 2012

Graphical Abstract

Abstract

Abstract

Objective To identify the related factors of bone mineral density reduction in postmenopausal women with early breast cancer 1 year after surgery. Methods The clinical data of 242 patients with early breast cancer of postmenopausal women in our hospital were collected and analyzed. Univariate and multivariate logistic regression model was used for analysis of related factors of bone mineral density reduction in postmenopausal women with breast cancer. Results Univariate logistic analysis on ten potential risk factors showed that age, BMI, Oral AI endocrine therapy, postmenopausal time and level of estradiol were signifi cant variables affecting bone mineral density reduction(P < 0.05). Multivariate logistic analysis showed that Oral AI endocrine therapy, long postmenopausal time and low level of estradiol were major risk factors( P < 0. 05). Conclusion Oral AI endocrine therapy, long postmenopausal time, low level of estradiol are major risk factors of bone mineral density reduction of postmenopausal women with early breast cancer. We should pay great attention to the patients with these risk factors and carry out appropriate treatment to decrease bone loss incidence.
- Breast neoplasms,
- Postmenopausal,
- Bone mineral density

FullText(HTML)

References (12)

References

[1]	Abdel-Razeq H, Awidi A. Bone health in breast cancer survivors[J]. J Cancer Res Ther, 2011,7(3): 256-63.
[2]	Bryce J, Bauer M, Hadji P. Aromatase inhibitor-associated bone loss[J]. Oncol Nurs Forum, 2011, 38(3): 273-6.
[3]	Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment[J]. Ann Oncol, 2011, 22(12): 2546-55.
[4]	Dawson-Huqhes B, Looker AC, Tosteson AN, et al. The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the usa: an update in NHANES 2005-2008[J]. Osteoporos Int, 2012, 23(3): 811-20.
[5]	Liu ZH,Zhu HM,Yang DZ,et al. Recommendations of the diagnostic criteria for osteoporosis in chinese(2nd draft)[J]. Zhongguo Gu Zhi Shu Song Za Zhi，2000，6(1)：1-3. [刘忠厚，朱汉民，杨定焯，等．中国人骨质疏松症建议诊断标准 (第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[6]	Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the united kingdom[J]. Br J Cancer, 2006, 94(1):30-5.
[7]	Geisler J, Lønning PE. Aromatase inhibitors as adjuvant treatment of breast cancer[J]. Crit Rev Oncol Hematol, 2006, 57(1): 53-61.
[8]	Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover[J]. J Clin Oncol, 2012, 30(7): 718-21.
[9]	Lønning PE. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?[J]. Anticancer Drugs, 2008, 19 Suppl 2:S11-3.
[10]	Lester JE, Dodwell D, Purohit OP, et al.Prevention of anastrozoleinduced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer[J]. Clin Cancer Res, 2008, 14(19): 6336-42.
[11]	Coleman R, Cook R, Hirsh V, et al. Zoledronic acid use in cancer patients: more than just supportive care?[J]. Cancer, 2011, 117(1): 11-23.
[12]	Kim JE, Ahn JH, Jung KH, et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the korean cancer study group (KCSG-BR06-01)[J]. Breast Cancer Res Treat, 125(1): 99-106.

[1]	NIU Xiaohui. Progress on Treatment of Bone and Soft Tissue Tumors[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 1-5. DOI: 10.3971/j.issn.1000-8578.2020.19.1241
[2]	LIN Shaokun, XIN Jun, ZHOU Jin, OUYANG Yong’e, XIN Minghua, XU Rong, CHEN Guangfu. Significance of Tumor Suppressor Gene TCF21 Promoter Methylation for Diagnosis and Prognosis of Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2016, 53(5): 375-381. DOI: 10.3971/j.issn.1000-8578.2016.05.012
[3]	XU Ruobing, XUE Hengchuan, WANG Jianping, WU Liang, WANG Jianming. Screening of Differential DNA Methylation Profile and Construction of Aberrant Methylation Panel in Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(01): 28-31. DOI: 10.3971/j.issn.1000-8578.2015.01.007
[4]	CHEN Beibei, MA Yijie, CHEN Xiaobing, LUO Suxia, LV Huifang, LI Ning. Methylation of Tumor Suppressor Gene TIP30 in Promoter Region for Colorectal Cancer Diagnosis and Prognosis[J]. Cancer Research on Prevention and Treatment, 2013, 40(04): 349-352. DOI: 10.3971/j.issn.1000-8578.2013.04.008
[5]	LI Yan-ni, WANG Yu-chuan, ZHANG Wei-ming. De Novo Methylation on c-myc and p16 Promoters in Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 730-733. DOI: 10.3971/j.issn.1000-8578.2009.09.003
[6]	LI Hai-ping, ZHANG Ji-cai, FENG Jing, YU Zong-tao, LV Jun. Detection of Promoter Hypermethylation and mRNA Expression of 14-3-3σ Gene in Tissues of Human Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(08): 572-575. DOI: 10.3971/j.issn.1000-8578.785
[7]	TANG Qi-bin, SHI Xue-tao, YI Long-hai, SUN Hua-wen, ZOU Sheng-quan. The Study of Relationship between Inactivation of Tumor Suppressor Gene Cluster Located in Chromosome 9p21 and Progression of Extra-hepatic Bile Duct Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(09): 523-525. DOI: 10.3971/j.issn.1000-8578.3163
[8]	CHENG Fan, ZHANG Xiao-bin, ZHANG Jie. The mutation and abnormal methylation of VHL tumor-suppressor gene in primary renal cell carcinoma[J]. Cancer Research on Prevention and Treatment, 2002, 29(01): 37-40. DOI: 10.3971/j.issn.1000-8578.120
[9]	Expression of P⁵³.Bcl-2.P¹⁶ and c-myc Genes in OvarianEpithelial Tumors[J]. Cancer Research on Prevention and Treatment, 1999, 26(6): 424-425.
[10]	Yang Hong, . Expression of Tumor Suppressor Gene P16 in Ovarian Neoplasm[J]. Cancer Research on Prevention and Treatment, 1998, 25(1): 20-22.

Cited By

Get Citation

PDF

XML

Article views (1526) PDF downloads (771)

Turn off MathJax

Article Contents

Abstract

References

Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Analysis on Related Factors of Bone Mineral Density Reduction in Postmenopausal Women with Early Breast Cancer One Year after Surgery

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content